{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:04:39Z","timestamp":1775228679087,"version":"3.50.1"},"reference-count":0,"publisher":"Therapeutic Guidelines Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aust Prescr"],"DOI":"10.18773\/austprescr.2022.044","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T21:05:00Z","timestamp":1657055100000},"page":"140-141","source":"Crossref","is-referenced-by-count":2,"title":["New drug: Onasemnogene abeparvovec for spinal muscular atrophy"],"prefix":"10.18773","volume":"45","member":"39051","published-online":{"date-parts":[[2022,7,7]]},"container-title":["Australian Prescriber"],"original-title":[],"link":[{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/onasemnogene-abeparvovec-for-spinal-muscular-atrophy.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:18:38Z","timestamp":1775225918000},"score":1,"resource":{"primary":{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/onasemnogene-abeparvovec-for-spinal-muscular-atrophy.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.18773\/austprescr.2022.044","relation":{},"ISSN":["1839-3942"],"issn-type":[{"value":"1839-3942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]}}}